Lymphoma News and Research

RSS
Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.
Simple urine test can accurately diagnose and track bladder cancer

Simple urine test can accurately diagnose and track bladder cancer

NCCN introduces first-ever evidence-based guidelines for pediatric bone sarcoma

NCCN introduces first-ever evidence-based guidelines for pediatric bone sarcoma

Study links immune status to herpesvirus retinitis progression

Study links immune status to herpesvirus retinitis progression

Insurance hurdles and costs hinder access to blood cancer drugs

Insurance hurdles and costs hinder access to blood cancer drugs

Scientists discover molecular pathway that controls cellular waste recycling

Scientists discover molecular pathway that controls cellular waste recycling

Multi-million dollar grants aim to advance hairy cell leukemia research

Multi-million dollar grants aim to advance hairy cell leukemia research

CRISPR activation library uncovers gene driving lymphoma growth and resistance

CRISPR activation library uncovers gene driving lymphoma growth and resistance

New AACR report outlines future of cutting-edge cancer research

New AACR report outlines future of cutting-edge cancer research

Cannabis-derived nanovesicles showed early antitumor potential in mice

Cannabis-derived nanovesicles showed early antitumor potential in mice

Ivonescimab shows significant survival benefit for patients with PD-L1-positive NSCLC

Ivonescimab shows significant survival benefit for patients with PD-L1-positive NSCLC

FDA clears trial of dual-targeted CAR T-cell therapy for cancer

FDA clears trial of dual-targeted CAR T-cell therapy for cancer

Biosimilars reduce financial burden for cancer patients and insurers

Biosimilars reduce financial burden for cancer patients and insurers

Egg yolk peptides protect brain cells from oxidative stress

Egg yolk peptides protect brain cells from oxidative stress

Optimized EAP regimen delivers outstanding mobilization effects in multiple myeloma and lymphoma patients

Optimized EAP regimen delivers outstanding mobilization effects in multiple myeloma and lymphoma patients

Protein degrader shows strong activity against treatment-resistant blood cancers

Protein degrader shows strong activity against treatment-resistant blood cancers

Younger mismatched donors offer new hope for blood cancer patients

Younger mismatched donors offer new hope for blood cancer patients

UC Irvine researchers develop framework to make CAR T-cell therapy safer

UC Irvine researchers develop framework to make CAR T-cell therapy safer

UVA researchers find how postoperative delirium may set the stage for dementia

UVA researchers find how postoperative delirium may set the stage for dementia

Aircrews face highest risk of radiation-related cancer deaths

Aircrews face highest risk of radiation-related cancer deaths

Cannabis compounds may weaken glioblastoma response to chemotherapy and radiation

Cannabis compounds may weaken glioblastoma response to chemotherapy and radiation

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.